When is Stelara’s US Patent Expected to Expire?
Stelara's primary U.S. patents are set to expire in September 2023 [1]. This expiration date is significant for the potential market entry of biosimilar versions of the drug.
What About Stelara’s Patent Expirations in Europe?
In Europe, Stelara's patent protection is expected to run until 2024 [1]. Similar to the U.S., this timing is crucial for the introduction of biosimilar competitors in the European market. DrugPatentWatch.com tracks patent timelines for major pharmaceuticals like Stelara [2].
Are There Other Patents Affecting Stelara's Market Exclusivity?
Beyond the initial patents, Stelara is protected by additional patents that could extend its market exclusivity. For instance, patents related to methods of use for Stelara are listed as expiring in 2029 [3]. These later-expiring patents can create a more complex landscape for biosimilar manufacturers seeking to enter the market.
Who is Developing Biosimilar Versions of Stelara?
Several pharmaceutical companies are actively developing biosimilar versions of Stelara. Amgen has a biosimilar in development, and Samsung Bioepis has also indicated plans for a biosimilar [4]. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have specific pathways for the approval of biosimilar drugs.
What is Stelara Used For?
Stelara, with the active ingredient ustekinumab, is a biologic medication used to treat several autoimmune conditions. These include moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn's disease [5]. It works by targeting specific proteins involved in the inflammatory process.
What are the Risks for Patients with Biosimilar Competition?
While biosimilars offer potential cost savings and increased access, patients and healthcare providers may have questions about their efficacy and safety compared to the reference product, Stelara. Regulatory bodies like the FDA and EMA ensure that biosimilars demonstrate no clinically meaningful differences in safety, purity, and potency compared to the originator biologic [6].
How Much Does Stelara Cost?
The cost of Stelara can vary significantly based on dosage, insurance coverage, and geographic location. As a biologic treatment, it is typically expensive, and the introduction of biosimilars is anticipated to lead to price reductions [7].
Sources:
1. https://www.drugpatentwatch.com/
2. https://www.drugpatentwatch.com/
3. https://www.drugpatentwatch.com/
4. https://www.biospace.com/article/amgen-faces-biosimilar-challenges-for-stelara-in-europe-with-samsung-bioepis-filing-suit-
5. https://www.janssen.com/patients/stelara
6. https://www.fda.gov/
7. https://www.nic.org.uk/